A Phase 1, Randomized, Double-blind, Placebo-controlled, Integrated Single Ascending Dose, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Latest Information Update: 24 Jun 2026
At a glance
- Drugs AMG 691 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors Amgen
Most Recent Events
- 17 Jun 2026 Planned End Date changed from 25 Oct 2026 to 10 Apr 2027.
- 17 Jun 2026 Planned primary completion date changed from 13 Sep 2026 to 10 Apr 2027.
- 17 Jun 2026 Status changed from recruiting to active, no longer recruiting.